S100A9 and breast carcinoma: Specifically for breast cancer, it is possible that S100A9-mediated immunosuppression (38) enables the liver tropism of sEVHYP-exposed luminal cells, while also promoting mammary gland transformation via transcriptional coactivation of cancer genes (32) and intercellular communication with transformed cells (39).